Table 1.
Characterization of SLNs and NLCs
| Systems | Particle size (nm) | PDI | Zeta potential (mV) | LID EE (%) | PRI EE (%) | LID DL (%) | PRI DL (%) |
|---|---|---|---|---|---|---|---|
| LID/PRI SLNs | 123.6±3.1 | 0.19±0.02 | +29.3±2.1 | 92.6±3.8 | 90.1±3.0 | 4.3±0.4 | 4.5±0.4 |
| LID SLNs | 119.9±4.1 | 0.21±0.03 | +23.1±2.3 | 93.2±3.2 | NA | 4.5±0.3 | NA |
| PRI SLNs | 124.5±3.5 | 0.19±0.03 | +21.4±1.9 | NA | 91.4±3.2 | NA | 4.6±0.2 |
| SLNs | 1,204±2.9 | 0.16±0.02 | +15.5±1.5 | NA | NA | NA | NA |
| LID/PRI NLCs | 176.3±4.7 | 0.26±0.03 | +21.2±1.8 | 91.2±4.2 | 90.4±3.4 | 2.2±0.3 | 2.3±0.3 |
| LID NLCs | 178.2±4.3 | 0.23±0.02 | +16.2±1.3 | 92.0±3.5 | NA | 2.3±0.2 | NA |
| PRI NLCs | 175.4±4.2 | 0.22±0.02 | +14.3±1.2 | NA | 91.2±2.8 | NA | 2.4±0.3 |
| NLCs | 174.9±3.9 | 0.20±0.02 | +7.8±0.9 | NA | NA | NA | NA |
Note: Data represent the mean ± SD (n=3).
Abbreviations: DL, drug loading capacity; EE, encapsulation efficiency; LID, lidocaine; NA, not applicable; NLCs, nanostructured lipid carriers; PDI, polydispersity index; PRI, prilocaine; SLNs, solid lipid nanoparticles.